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Abstract
The purpose of this study was to focus on whether solely obesity (measured by BMI)
leads to an increased risk of COVID-19 mortality in terms of excess in-hospital deaths. As the
grim milestone of one million deaths in the United States from COVID-19 was reached, one
could assume the disease would continue to coexist with humanity in the long term. While
vaccination continued to limit the spread of COVID-19, it was essential to investigate risk
factors that may exacerbate the severity of the illness in humans. Obesity is already a global
pandemic affecting 40% of Americans and over 650 million people worldwide. Obesity is
connected to an entire range of clinical conditions including some of the leading causes of death
worldwide making it a more generalizable statistic. Furthermore, the purpose of this study was to
conduct a systemic review of major risk factors between obesity and COVID-19, and this
analysis shall ascertain which factors have the most predictive value in determining mortality
and severity of the condition. Ten research studies of 3,780,926 COVID-19 patient cases were
included. Meta-analysis results indicate a pooled OR of 0.93 (0.71-1.23, p = 0.627) for inhospital mortality of obese patients relative to non-obese patients when adjusted for confounders.
All comorbidities associated with the development of severe disease were found to have an equal
chance of leading to mortality. In other words, obesity did not lead to a statistically significant
risk of dying from COVID-19.
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Introduction
The Convergence of Obesity and SARS-CoV-2:
Across 168 countries, a 1% increase in obesity prevalence saw an 8.3% increase in
COVID-19 mortality rate and a 6.6% increase in COVID-19 case rate [22]. This is mediated
through a variety of risk factors including psoriasis, diabetes, stroke, excess adiposity, and much
more. Patients diagnosed with obesity and SARS-CoV-2 are more likely to be hospitalized,
placed on intensive mechanical ventilation (IMV), or faced with severe symptoms [3]. The goal
of this study is to systematically analyze the variety of risk factors and mediating variables
behind COVID-19 outcomes in obese patients. So far, while there have been many studies on
obesity and COVID-19, none have attempted to summarize the relationship between the two
diseases and elucidate the strongest possible correlations.
In December 2019, a virulent strain of severe acute respiratory-related coronavirus
(SARS-CoV-2) gradually spread amongst the residents of Wuhan in the People’s Republic of
China. Now known as COVID-19, as of 10 August 2020, there were 19,718,030 confirmed cases
and 728,013 confirmed deaths reported in 216 countries, areas, or territories [32]. However, the
scale of the current pandemic has opened new avenues for studying the interplay of various
conditions known to cause chronic illness and death. COVID-19 or severe acute respiratory
syndrome coronavirus (SARS-CoV-2) is known for rapid infectivity and a high contagion rate
[50].
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For example, while previous disease outbreaks of SARS were localized, COVID-19 has
interacted with a larger more diverse human population currently seeing the gradual rise of a
chronic disease of its own: obesity. Obesity is defined as the accumulation of excess body fat
which can be measured using BMI or body mass index. A BMI ≥ 30 kg/m² is defined as obese
except for Asian populations where the cutoff is lower at around 27 kg/m² [1]. As a
multifactorial disease, obesity has been linked to a wide variety of conditions ranging from
hypertension to coronary artery disease (CAD). With 650 million obese adults within a
population of 1.9 billion overweight adults 18 years or older, the prevalence of obesity is too
high to ignore and growing rapidly [46].
Such a huge and vulnerable population is unique in its overall physiological makeup
which means the obese population’s epigenetic profile could make it susceptible to the severe
side-effects of COVID-19. As COVID-19 becomes a mainstay, the need to ensure that those with
comorbidities as common as obesity are taken care of is necessary to ensure the control of this
virus and a reduction in deaths. A major goal of this thesis is to discuss a series of risk factors
and mediating variables that have the potential to contribute to the severity in obese patients with
COVID-19 and the application of meta-analysis framework can accomplish this.
Clinical Diagnosis & Management of COVID-19:
COVID-19 is transmitted by the virus SARS-CoV-2 in the respiratory system causing the
following flu-like symptoms: fever, cough, sputum, rhinorrhea, sore throat, headache,
conjunctivitis, and gastrointestinal issues [50]. The clinical showcase of the disease appears two
weeks after exposure with a median incubation period of about 5 days on average for all current
strains in the coronavirus family [50]. However, newer strains such as Omicron can show up in
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as little as two to five days. The virus is transmitted through human-human air transmission
whereby it begins to infect the body through direct contact with mucous epithelial membranes of
the respiratory tract [50].
Despite the possibility of acute symptoms, COVID-19 presentations vary from
asymptomatic to acute respiratory failure [50]. Acute respiratory distress syndrome (ARDS) and
acute lung injury (ALI) are two of the primary outcomes in morbidity and mortality among all
COVID-19 patients [53]. ARDS was found to be a predictor of 60-day mortality by a hazard
ratio of 1.67 (95% CI 1.05–2.64) in a study of 239 critically-ill COVID-19 patients [70]. The
course of the illness is mild or asymptomatic in about 80-90% of cases with RT-PCR throat swab
results coming back negative in most cases [50]. The remaining 15% of cases are either serious
or critical in about 10% and 5% of cases respectively [50]. In cases that were serious, symptoms
reported include dyspnea and hypoxemia while patients under critical condition developed
respiratory failure, pneumonia, shock, multiorgan failure, or sometimes even death [50]. Within
the group of hospitalized patients, about 10–20% were admitted to the intensive care unit, 3–10%
required a breathing tube and 2–5% passed away [50]. The overall mortality rate was found to be
between 2-5%; however, the rates are confounded due to the disparity in study locations with
higher mortality found in studies done near pandemic hotspots [50]. There was no differential
data regarding specific strains or time frames.
The most common non-invasive laboratory test done for COVID-19 is RT-PCR which
uses nasal swab, tracheal, or bronchoalveolar specimens to detect SARS-CoV-2 RNA [50]. In a
random sample of 1099 COVID-19 patients, lymphocytopenia (low lymphocyte count) was
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present in 83% while 36% had thrombocytopenia (low platelet count), and 34% had leucopenia
(low white blood cell count) [50]. Other tests such as full chest X-rays and CT scans have also
been used to identify pathological findings such as subpleural lesions or edema in extreme cases
where a differential diagnosis is necessary to rule out other causes [50].
At this time, multiple vaccines have been developed and are currently used to prevent
spread of COVID-19 while limiting the possible severity of the virus in uninfected individuals.
Beyond that, there is no definitive evidence pointing to the efficacy of steroids and antibiotic
prophylaxis [50]. Antiviral drugs such as remdesivir and molnupiravir have been approved by the
CDC (Centers for Disease Control and Prevention) due to their performance against other strains
of coronavirus by targeting key inflammatory immune pathways known to cause cytokine storm
which can kill COVID-19 patients by disrupting the alveolar capillary barrier. Dexzoplicone, a
hypnotics medication for insomnia that regulates GABA signaling, may be a treatment as it led to
77/82 favorable outcomes in the experimental group [31]. Finally, respiratory therapy is an
important viable option for patients with hypoxia who cannot reach a stable arterial oxygen level
due to respiratory crisis [50].
Clinical Diagnosis & Management of Obesity:
Obesity is a public health crisis with long-term consequences especially in accordance
with the current COVID-19 pandemic. When compared to individuals with normal BMI,
individuals with obesity have a greater risk of hypertension, dyslipidemia, insulin resistance, type
2 diabetes mellitus (T2DM), cardiovascular disease and cerebrovascular dysfunction, all of
which are recognized as comorbidities for poor outcomes in COVID-19 patients [54]. BMI is the
most common measure of body mass with cutoffs for overweight and obesity at 25 kg/m² and 30

5

kg/m², respectively. When it comes to measuring obesity more specifically, BMI can be used to
divide obese individuals into classes: class I (30.0-34.9 kg/m²), class II (35.0-39.9 kg/m²), and
class III (40 kg/m² and above). In a meta-analysis of 17 studies with 543,399 patients, BMI
stratification found that the pooled risk ratio for COVID-19 mortality increased from 1.27 for
class I to 1.92 for class III obese patients [52]. Morbidly obese (BMI ≥ 35) were found to have a
7-fold relative risk of severe COVID-19 illness compared to normal weight subjects [61].
Beyond that, morbid obesity came with a higher risk for severity and mortality of both influenza
(OR = 1.40, CI: 1.10-1.79) and COVID-19 (OR = 3.76, CI: 2.67-5.28) making a significant
subsection of the obese population extremely at-risk to multiple diseases at once [74].
When assessing the relationship between BMI and mortality, higher risk of death was
found in the lower and upper ranges, but not in the middle. BMI or body mass index is imperfect
as it does not consider excess adipose tissue and actual body fat percentage irrespective of lean
muscle [46]. For example, muscular athletes tend to have a high BMI which is capturing the
effect of muscle mass not actual fatty tissue, and Asian populations tend to have higher visceral
fat percentage at lower BMI levels leading to an underestimate in the numbers of obese people
[46]. However, BMI-controlled abdominal obesity measured by waist circumference in subjects
was shown to have a positive linear correlation with mortality risk [46].
Instead of BMI, certain molecular biomarkers have been found to better illustrate the way
obesity damages the body allowing for better diagnosis. Adipokines such as leptin, adiponectin,
and resistin are hormones secreted by adipose tissue along with cytokines TNF-α and IL-6 [43].
All of them are found in increased concentrations (except for adiponectin which is decreased)
leading to chronic inflammation, insulin resistance, and hyperinsulinemia due to lack of negative

6

feedback from bound insulin receptors [46]. This can lead to increased chronic disease risk for
type II diabetes, cardiovascular disease, and cancer [46]. Molecular signaling markers for
inflammation, such as the cytokines, further highlight the pathogenesis of this condition. Tumor
necrosis factor and interleukin-6 are upregulated, causing activation of liver secretion of Creactive protein which is an inflammatory marker associated with increased risk of CHD,
ischemic stroke, cancer, and death [46].
Obesity management requires the use of pharmacological and nonpharmacological
interventions in tandem with an individualized diet plan. A high-fat low carbohydrate diet has
been found to lower the risk of obese patients having to use a ventilator [39]. A normal calorieintake (eucaloric) ketogenic diet (EKD) can more specifically attenuate the effects of cytokine
storm syndrome by inhibiting aerobic glycolysis in active macrophages limiting their
inflammatory functions [39]. If possible, surgical interventions can be done through bariatric
surgery; however, patients run the risk of getting infected which lowers the efficacy of surgery as
a clinical option [46]. Total lung capacity can be restored through bariatric surgery in obese
patients as a preventative measure against respiratory distress caused by COVID-19 [65]. While
obesity can be treated with various invasive and non-invasive interventions, prevention is still the
best option.
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Contextual Review of Obesity, COVID-19, and any Related Mechanisms or Diseases
When obesity and COVID-19 come together, it can lead to physical and mechanistic
changes which can cause new diseases or worsen preexisting conditions. For example,
pulmonary dysfunction in an obese COVID-19 patient can lead to metabolic imbalances like
hypoxia along with immune impairments and adipose inflammation [53]. This can aggravate
other comorbidities eventually manifesting in negative patient outcomes if no vaccine is taken to
generate an adaptive immune response. For example, metabolic associated fatty liver disease
(MAFLD) is an at-risk group for respiratory diseases like COVID-19. The presence of obesity in
MAFLD patients came with a 6-fold risk of severe COVID-19 even after adjusting for age, sex,
smoking, diabetes, and other confounders [75]. MAFLD is just one of many comorbidities
known to enhance COVID-19 severity in obese patients.
Nonetheless, obesity as a predictor of mortality depends on what measure one applies.
Since the experimental design of this meta-analysis uses BMI, that is where to start. BMI follows
a J-shaped curve when measured against total and cardiovascular mortality with overweight
(25.0-29.9 kg/m²) and mildly obese (30.0-34.9 kg/m²) groups showing the lowest levels of
mortality due to the presence of lean muscle mass instead of actual adipose tissue which BMI
cannot differentiate between [10]. For example, in a study of 300 COVID-19 patients at
Montefiore Medical Center, the 30-day mortality rate was 52.7% yet the relative risk dipped
from 1.47 for overweight patients to 1.35 for the class I obese group despite overlapping
confidence intervals [11].
Unlike BMI, VAT directly measures the area of visceral fat accumulation in the abdomen
using CT scans allowing for confounders such as lean muscle to be eliminated from contention
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[67]. Visceral fat is known to contain adipocytes which secrete interleukin-6: a key biomarker for
obesity known to activate pro-inflammatory pathways that can cause cytokine storm in response
to a pathogen like SARS-Cov-2 [67]. Within a sample of 150 patients divided into four VAT
quartiles and stratified by gender, lung severity score (LSS), and age, there was a direct linear
relationship between VAT accumulation and ICU admission (%) [67]. Furthermore, patients who
were over 65 years of age, male, and or had a high LSS were found to be at greater risk for ICU
admission and intubation especially if they had a high VAT [67].
Looking at waist measures, the risk of cardiac events increased by 2% for every 1 cm
increase in waist circumference, and by 5% for each 0.01 increment in waist-to-hip ratio [10]. To
ascertain risk between different cardiovascular events, waist-to-height ratio proved more
successful than BMI in a meta-analysis of 88,000 participants [10]. A version of waist-to-height
ratio called the waist index is calculates using waist circumference in centimeters adjusted for
height cubed as a measure of volume [10]. Waist index has proven to be most associated with a
history of myocardial infarction in a study of 16,778 patients in the United States, and it is the
only measure that can discriminate between low, medium, and high-risk categories for the
cardiac event [10]. The population risk for myocardial infarction was 24.3% for waist to-hip ratio
in comparison to 7.7% for BMI when comparing the highest quintiles [10]. In place of BMI,
VAT and other measures of central obesity may serve as additional parameters for future studies.
Certain mediating variables were found to exacerbate the effects of obesity on infected
patients. For example, type II diabetes is known to cause insulin resistance and hyperglycemia
which results in glycation of angiotensin-converting enzyme II (ACE2) and other key proteins
stimulating inflammatory cytokines and thicker pulmonary walls leading to restrictive lung
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disease and pneumonia [56]. The resulting cytokine surge occurs concurrently and synergistically
in obese patients who already have the same symptoms. Type II diabetes mellitus and obesity
thus act in tandem to weaken the body’s immune defenses allowing SARS-CoV-2 to run rampant
in patients leading to greater severity and mortality. A fasting blood glucose level above 126
mg/dL is a common predicative marker for in-hospital mortality [56]. Thus, diabetics may have
an increased risk for COVID-19 severity although more research remains to be done to verify
this.
Other common comorbidities that are overrepresented in admitted COVID-19 patients
include hypertension and cardiovascular disease. A meta-analysis review of six publications
covering 1,527 COVID-19 patients reported prevalence rates of 17.1%, 16.4%, and 9.7% for
hypertension, cardiovascular disease (CVD), and diabetes mellitus (DM) respectively [38].
Furthermore, in a much broader study done in China with 44,672 COVID-19 patients, the fatality
rates themselves were 10.5% for CVD, 7.3% for DM, and 6.0% for hypertensive patients. This
occurred concurrently with another mediating variable that affects all people: age. Mortality rates
in the China study were 8.0% for the 70-79 age group and 14.8% for those over the age of 80
[38]. So, while aging may not be a comorbidity, its effects on the body in terms of cellular
breakdown and accumulation of cellular waste can worsen pre-existing conditions allowing
COVID-19 to inflict greater harm.
The most common complication of COVID-19 is severe acute respiratory syndrome with
extensive pulmonary fibrosis (PF) [36]. Adipocytes and their regional variants, pulmonary
fibroblasts, upregulate angiotensin-2 converting enzyme (ACE2) expression in adipose tissue of
obese and diabetic patients [36]. ACE2 is a common receptor on adipocytes that acts as a key
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gateway for SARS-CoV-2 entry into the body [5]. Even though ACE2 counters ACE1’s
inflammatory effects, the entry of SARS-CoV-2 causes viral shedding and rapid deterioration of
the body’s immune system through downstream effects in the renin-angiotensin pathway leading
to greater oxidative stress, vasoconstriction, and inevitable inflammation [5]. Since obese
patients have greater stores of adipose tissue, the effects of COVID-19 are multiplied.
Pulmonary distress is accelerated by the development of pulmonary lipofibroblasts in the
alveolar interstitial layer and other pulmonary endothelial basement layers in the presence of
adipocyte precursors in obese subjects which are also potential reservoirs for viral infections
[36]. The presence of viruses like SARS-CoV-2 is solely responsible for the development of
pulmonary fibrosis (PF) which is a common killer in obese patients with COVID-19 [36]. The
use of transcription factor agonists, weight loss strategies, and pharmacological therapy are all
routes for stemming PF and lowering mortality risk in obese COVID-19 patients [36]. Possible
curative measures for COVID-19 in obese patients may require an alternative route through
treating underlying conditions like PF. COVID-19 mortality occurs in obese patients through
inflammation in the lungs which can rapidly worsen into disease states such as acute respiratory
distress syndrome (ARDS) or pulmonary fibrosis (PF).
Moving on from COVID-19 severity, a commonly cited patient outcome is ICU
admission. While not a direct indicator, ICU admission does indicate a decline in patient health
and correlates with COVID-19 severity while serving as a precursor to patient mortality. In
Argentina, a multicenter prospective cohort study found that obesity is a major factor in ICU
admissions for adults (OR 2.38; 95% CI 1.51–3.70) [12]. In a meta-analysis of 20 studies, 85.6%
of their combined COVID-19 patient population (n = 7671) was hospitalized in ICU, 44.9% on
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average were obese, and a mean of 20.4% had died [15]. 19/20 studies showed higher
hospitalization rates for obese versus non-obese patients, 14/20 showed a greater prevalence of
complications in obese patients, and 4/20 publications revealed higher mortality rates in SARSCoV-2 infected obese patients [15].
Another important measure of COVID-19 severity is intensive mechanical ventilation
(IMV). Mechanical ventilation allows patients to receive oxygen when undergoing severe
respiratory distress. The odds ratio for IMV in patients with BMI > 35 versus patients with BMI
< 25 was 7.36 (1.63-33.14; P = 0.02) in a French study of 124 COVID-19 ICU patients [62]. A
higher share of IMV-receiving patients was obese compared to the overall pool of patients at a
Manhattan hospital with 43.4% obese versus 35.8% for the overall group of 393 patients [24].
According to a meta-analysis of 6081 patients across 11 cohort studies, there was a 16%
increased risk of invasive mechanical ventilation (OR 1.16, 95% CI 1.10–1.23, P < 0.0001) and a
20% increased risk of admission to ICU (OR 1.20, 95% CI 1.11–1.30, P < 0.0001) for every 5
kg/m² increase in BMI [17]. In a study of 442 patients at Cedars-Sinai Health System, obese
patients were twice as likely to require advanced care in the form of intubation or ICU
hospitalization relative to the odds of the non-obese controls [19]. Obesity was a significant risk
factor for intensive care unit (ICU) admission (OR = 1.21, CI: 1.002-1.46; I2 = 0.0%) and for
invasive mechanical ventilation (IMV) (OR = 2.05, CI: 1.16-3.64; I2 = 34.86%) in COVID-19
[21]. Overall, these indicators serve as a dependable proxy for measuring the severity of COVID19 in at-risk groups.
COVID-19 is exacerbated by obesity through a variety of physiological mechanisms,
some of which have already been mentioned. Increased ACE2 expression facilitates viral
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entrance into somatic cells especially adipose tissue [16]. Cytokine storm due to excessive
immune signaling and high ferratin levels further weakens the body’s defenses enhancing
severity [16]. Lastly, vitamin K deficiency, hyperleptinemia, and endothelial dysfunction
increase the risk of clotting or hemorrhage [16]. Alcohol consumption can even mediate the
effects of obesity on COVID-19 severity. Heavy drinking (HR = 2.07, 95% CI 1.24–3.47; q =
0.054) correlated with a higher risk of mortality in patients with obesity and COVID-19, but not
in non-obese COVID-19 patients [20]. Other lifestyle factors such as smoking and physical
activity when combined with alcohol consumption can provide an overall lifestyle score which
mediates obesity and worsening COVID-19. A UK Biobank study found that patients in the
worst lifestyle score category had a 4-fold greater dose-dependent increase in COVID-19 risk
compared to people with the best lifestyle score [27]. All of this indicates that there is a diversity
inherent in how various physiological processes dictate disease severity especially in groups with
prior health issues.
Most studies usually control for factors such as age and sex primarily because they also
have profoundly serious effects on COVID-19 outcomes. Morbidly obese patients (BMI ≥ 35)
who were less than 60 years of age were 2.2 (95% CI 1.7-2.9, p<.0001) and 3.6 (95% CI 2.5-5.3,
p=<.0001) times more likely to be accepted for acute and critical care while patients greater than
or equal to 60 years of age did not see a statistically significant likelihood in comparison [37]. In
a prospective cohort study of 5,279 patients, age was the strongest risk for hospital admission
with OR > 2 for all age groups over 44 years with the 75 and older group having an OR of 37.9
[51]. Being male is also an independent predictor of COVID-19 mortality with a hazard ratio of
1.52 (95% CI 1.33-1.73) [4]. Males and those who are older tend to be at greater risk of COVID-
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19 mortality barring exceptions where a younger, more female cohort displays higher mortality
rates due to differences in obesity classification and comorbidity presence.
Due to the presence of metabolic diseases besides obesity, the effects of COVID-19 are
exacerbated. This is important to understand as obesity can be a mediating variable while other
diseases may mask or contribute to the relationship between obesity and COVID-19 patient
outcomes. Psoriasis is an autoimmune disease with cutaneous symptoms that shares similar
inflammatory pathways such as CDKAL1 and ApoE with cardiometabolic diseases and COVID19 [40]. Hypoxemic respiratory failure is another condition that necessitates mechanical
ventilation for COVID-19 patients while pulmonary capillary microangiopathy is a shared
symptom between COVID-19 and H1N1 influenza, furthering the links between COVID-19 and
pulmonary comorbidities while obscuring other ties to obesity [41]. For example, the obese
group in a study on 100 patients with COVID-19 pneumonia were found to have lower PaO2 and
required higher volumes of oxygen for a longer time [44]. Because obesity tends to be present in
those with underlying complications, determining COVID-19 as the cause of death while tracing
it to one disease only can be exceedingly difficult.
The main cause of excess mortality in obesity is cardiovascular disease which is a
common comorbidity among COVID-19 patients [47]. In a case series study of 5,700 COVID-19
patients in New York City, hypertension was the most common comorbidity present in 56.6% of
the sample with a greater fraction of hypertensive patients dying relative to the share of the nonhypertensive group [57]. In fact, the exaggerated presence of such disorders makes it hard to
truly identify COVID-19 as the true cause of death in patient cases. For example, almost 60% of
the 3,032 COVID-19 mortality cases studied in Italy were found to have three or more
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comorbidities [49]. It is important to control for various comorbidities before drawing
conclusions regarding their individual and separate effects.
Not all of the variability in COVID-19 outcomes are due to factors outside of one’s
control. Looking at per-capita consumption of sugar and seafood along with reported rates of
depression across 156 countries, sugar consumption and depression were positively correlated
with crude mortality rates while seafood consumption negatively correlated with the infection
fatality rate [55]. Certain COVID-19-induced inflammatory pathways related to IL-6 and Creactive protein are known to be upregulated at the onset of depression [55]. In regard to dietary
factors, they act indirectly since poor diet is commonly associated with poor physical activity and
a higher likelihood of comorbidities known to be present in deceased COVID-19 patients [55].
While genetic influences the likelihood of having certain metabolic illnesses, it does not solely
influence COVID-19 disease severity or prevent positive changes to one’s health.
One of the top ten major comorbidities associated with COVID-19 is chronic kidney
disease (CKD). In the presence of obesity, the kidney undergoes major physiological changes
including glomerular capillary hypertension, enlarged glomerulus, and podocyte dysfunction to
name a few [58]. Since the kidneys play a key role in ACE2 expression, any damage to the
kidneys may also affect viral shedding in adipose tissue leading to increased presence of
COVID-19 long-term. Every 1 kg/m² increase in BMI is associated with a 14% increased risk for
COVID-19 hospitalization with a majority the risk being explained for by genes linked to
increase body mass which has downstream effects in the form of increased likelihood of having
type II diabetes (T2DM), CKD, and coronary artery disease [59]. Such risk factors interfere with
immune system functioning by disrupting the inflammatory lipid mediators that respond to viral
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entry in adipose tissue. Sure enough, a study of 67 lipid mediators found that all but three
strongly correlated with BMI as a pattern of disease severity while hypertension and heart
disease also showed similar albeit less strong relationships [60].
Another major mediating factor for obesity-related COVID-19 mortality is diabetes,
especially T2DM. Diabetes affects the regulation of blood glucose levels in the body and can
lead to hyperglycemia and insulin resistance in some cases. This occurs in obese patients due to
free fatty acids and macrophage invasion due to improper immune signaling which disrupts
insulin release [16]. Among 461 COVID-19 patients treated in six hospitals in Guangdong,
China, free blood glucose level on admission (OR per mmol/l 1.22; 95% CI 1.05–1.40) was
independently correlated with poor 30-day outcome [64]. In a whole-population study of
registered patients in England (n = 61,414,470), the multivariate adjusted risk for in-hospital
COVID-19-related mortality was 2.86 (95% CI 2.58–3.18) for patients with type 1 diabetes
mellitus (T1DM) (n = 263,830) and 1.80 (95% CI 1.75–1.86) for those with T2DM (n =
2,864,670) [64]. Furthermore, over 85% of severe COVID-19 cases in a multicenter study in
China had diabetes or cardiovascular disease [68]. The presence of widespread metabolic
disorders like diabetes and cardiovascular disease influences obesity prevalence and its
relationship with COVID-19 mortality.
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Figure 1. Course of disease progression highlighting major causes and comorbidities that lead to COVID-19
mortality in obese patients.
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Research Design and Methods
Study Selection:
The data for this review is drawn from a wide variety of sources including PubMed
[MEDLINE], Web of Science, Google Scholar, OVID, UCF Primo Catalog, Europe PMC, and
CINAHL. Research papers were found using medical subject headings (MeSH) as follows:
COVID-19 mortality (or SARS-CoV-2 deaths or COVID-19 hospitalizations or coronavirus
deaths or COVID-19 severity) and obesity (or BMI or visceral fat or excess adiposity or
lipidemia or overweight). Study selection is done using EndNote 20 citation software which
excluded any retracted articles along with duplicated titles. Biased studies that contradicted one
another were excluded using Newcastle-Ottawa Quality Assessment Scale (NOS). Publications
with more than seven stars, 5–7 stars, and 0–4 stars were categorized as high, intermediate, and
low in terms of quality each. Meta-analysis and systemic reviews were included as preexisting
sources for additional data and statistical background. Author, publication type, date, country of
origin, sample size, and other contextual factors were considered as well to ensure diversity in
source material and proper validity and generalizability of results.
Initially, 22,890 articles were excavated from a variety of databases. To broaden the
search, no additional filters were used and generalized search terms including “Obesity and
COVID-19 mortality”, “relationship between obesity and SARS-CoV-2”, “30-day mortality of
obese and non-obese patients”, and various other iterations were used. Twelve other sources
were found through non-database searches either directly from UCF Library or search engine
advanced queries. Around 851 research articles were isolated for immediate further screening
after cutting out foreign language, duplicate, and poorly sourced papers lacking credibility.
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Credibility was determined through advanced search by selecting for articles related to the
subject of Public Health and Biomedical Sciences, the COVID-19 pandemic, obesity, and patient
outcomes such as 30-day mortality or COVID-19 severity.
When it comes to narrowing the list from 851 to 75 research publications, articles were
sorted and organized based on citations, references, clinical relevance, article type, and presence
of quantifiable variables for obesity and patient outcome. Around 776 articles were excluded
because of their inability to meet sufficient criteria. The remaining seventy-five papers all
contained sufficient information regarding the interconnections between two major global health
pandemics: obesity and COVID-19 along with contextual data regarding their collective effect
on a variety of patient outcomes ranging from ICU admission to need for mechanical ventilation.
Since the purpose of this meta-analysis review is to study the sole effect of obesity on death from
COVID-19, qualitative systemic reviews and meta-analyses could not be used as a source for
data analysis. In addition, there were multiple retrospective and prospective patient studies that
had to be excluded due to lack of cross-sectional analysis of survivors and non-survivors
according to the presence of obesity. A few studies even had to be removed because of unclear
BMI cutoffs or the use of less common obesity measurements such as visceral adipose tissue
percentage (VAT) or waist circumference. After that, seventeen studies remained for further
analytical evaluation with ten selected for meta-analysis.
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Records Identified Through
Database Queries

Records Found Through
Other Sources

(n = 22,890)

(n = 12)

Records After Duplicates and Non-English Copies
Removed
(n = 851)

Records Screened

Records Discarded by
Filtering Titles/Abstracts

(n = 851)
(n = 776)

Full-text publications
assessed for eligibility
(n = 75)

Records Removed:
Meta-Analyses (n = 16)
Literature Reviews (n = 17)
Incomplete Data (n = 25)

17 studies with obesity and mortality
endpoints

Records Excluded:
Hazard Ratios Only (n = 5)
No Cross-Sectional Data (n = 2)

10 studies with ORs and cross-sectional
obesity/mortality data for meta-analysis

Figure 2. Flow diagram displaying literature screening, review, and selection.

20

Data Analysis:
To objectively measure how COVID-19 heightens risk of death for obese patients, three
additional clinical risk outcomes were measured using odds ratio (OR) with a 95% confidence
interval (CI): hospitalization rate, mechanical ventilation (IMV), and placement in intensive care
unit (ICU). Tabulations assessing the common characteristics of all studies such as gender,
comorbidities, patient outcomes, and sample size were also given along with scatterplots,
logistical regression models and forest plots for measuring the relationship between obesity and
risk of SARS-CoV-2 infection. Dose dependent studies with the right measurements were
measured along the plots in subgroups based on common study characteristics such as location.
Finally, hazard ratios for various body fat measurements were obtained to assess the impact of
obesity on COVID-19 severity according to relative risk of catching and dying from the disease.
While BMI is an important metric, VAT or visceral adipose tissue as measured by
computed tomography (CT) scans is the preferred complementary indicator for grading obesity.
Additional measurements such as waist circumference, waist index, and waist-to-hip ratio may
also function in assessing overall adiposity in lieu of BMI which tends to underestimate
cardiovascular stress stemming from obesity. These would serve as the operational definitions of
obesity as a risk factor if there were enough additional studies to conduct a proper analysis of
their effects on in-hospital mortality.
For each study, odds or hazard ratios should be calculated or obtained to measure the
effect of obesity on in-hospital deaths from COVID-19. A summary statistics table of seventeen
studies including OR, HR, 95% CI, adjustments, and study quality were provided in addition to a
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general overview table detailing study qualities such as COVID-19 outcomes and obesity
parameters. A variety of statistical software platforms were used such as IBM SPSS and JASP.
In the end, MedCalc software was used to calculate odds ratios and conduct a meta-analysis. The
meta-analysis used discrete outcomes from four discrete groups: total number of positive cases
(mortality) in the intervention group (obese), total number of positive cases in the control group
(non-obese), total number of cases in the intervention group, and total number of cases in the
control. A test for heterogeneity was done to measure study variation using Cohen’s Q and I²
statistics. Tests for publication bias were done in the form of Egger’s test and Begg’s test to
ensure that the data provided is dependable and accurate. Finally, a forest plot was constructed to
visualize the odds ratios including pooled ORs for the fixed effects and random effects models.
Importance of Findings:
The expected results for this study would naturally indicate a clear positive linear
correlation between obesity and severity or mortality in COVID-19 cases. Based on previous
studies, one would expect an odds ratio of about 1.5-2.0 in favor of increased risk of death for
obese patients suffering from COVID-19. This assumption is based on the pattern of results
procured from prior studies and mentioned in the systemic review. The relative risk of COVID19 mortality would display a strong direct correlation with BMI.
The purpose of these findings is not only to demonstrate that obesity is linked to COVID19 severity and mortality, but also to elucidate mechanisms for further study. While waist
circumference, VAT, and waist index are all relatively accurate and standardized estimates of
excess adiposity, this study focuses on BMI as the main obesity parameter since it is more
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commonly used. In the future, physiological experimental studies beyond the scope of this
review could be done to compare the presence of certain biomarkers in the body and their effects
on COVID-19 outcomes in obese patients.
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Results
Seventeen studies were selected for advanced analysis and ten were chosen for the metaanalysis due to their presence of odds ratios and the underlying data needed to measure them.
4,886 obese patients died of COVID-19 compared to 10,907 non-obese patients. According to
Table 5, the total patient sample included 3,780,926 obese patients and 13,526,235 non-obese
patients. A sum of 17,307,161 COVID-19 patients were analyzed in all ten studies. Figure 2
illustrates that the random-effects model detected an OR of 0.933 (95% CI 0.707-1.232; p =
0.627) which is a non-significant value indicating no serious effect of obesity on COVID-19
mortality risk. In Table 6, the heterogeneity test displayed and I² of 96.44% (95% CI 94.91%97.50%) which means a significant diversity in publications studied. Table 7 shows that both the
Egger’s and Begg’s tests returned non-significant p-values making the meta-analysis void of
publication bias. Overall, the outcome of this study contradicts the expected result of statistically
significant increased odds of dying from COVID-19 for obese patients. The meta-analysis data
suggest that obesity is not a major risk factor in COVID-19 mortality. Rather, underlying
comorbidities related to obesity play an outsized role in mediating COVID-19 severity. This
obfuscates obesity’s true relationship with COVID-19 by potentially exaggerating the effects of
excess adipose tissue on patient outcome.
The results do not completely rule out obesity as a significant factor in COVID-19
outcomes. Very few studies only focused on in-hospital mortality due to lack of recorded deaths.
Instead, COVID-19 severity was seen as more comprehensive by focusing on all patient
outcomes including mortality, ICU admissions, and IMV to name a few. While ten studies barely
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make the cutoff for statistical power, their shared parameters, geographic diversity, and large
samples make the data more accurate.
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Author

Year

Region

Patient Source

COVID-19
Cases
Positive Cases:
51663
Negative Cases:
98567

Age (mean or
median yrs.)
Positive = 46.65
Negative = 40.25
Suspected = 43.3

Male
(%)
51

Bello-Chavolla et al.

2020

Mexico

General Directorate of
Epidemiology of Mexican
Ministry of Health

Berenguer et al.

2020

Spain

COVID@Spain

4035

70

61

Cariou et al.

2020

France

CHU Nantes and 53 hospital
centers

1317

69.8

64.9

12 kidney transplant centers

144

62

66

NY-Presbyterian/Columbia
Irving Medical Center
ISARIC WHO CCP-UK (206
acute care hospitals)
Luigi Sacco Hospital

1150

62

67

20133

73

60

233

62

69.1

Cravedi et al.

2020

Cummings et al.

2020

USA
Italy
Spain
USA

Docherty et al.

2020

UK

Giacomelli et al.

2020

Italy

Hajifathalian et al.

2021

USA

NY-Presbyterian and Weill
Cornell Medical Centers

770

63.5

61

Halvatsiotis et al.

2020

Greece

90

65.5

80

Hendren et al.

2021

USA

University Hospital ‘‘Attikon”
‘‘Evangelismos” General
Hospital ‘‘Thriassion” General
Hospital ‘‘Ahepa” University
Hospital
‘‘G. Papanikolaou” General
Hospital ‘‘Agios Dimitrios”
General Hospital Patras
University Hospital
‘‘Koutlibaneio” General
Hospital
AHA Cardiovascular Disease
Registry

7606

63

55

Outcomes

Parameters

Hospitalization
ICU admission
In-hospital mortality
Positive test
IMV
In-hospital mortality

BMI ≥ 30

BMI > 30
BMI ≥ 30

In-hospital mortality & tracheal
intubation with mechanical ventilation
In-hospital mortality
Acute kidney injury
IMV
In-hospital mortality
IMV
ICU admission
In-hospital mortality
30-day in-hospital mortality

BMI ≥ 30
BMI ≥ 30
BMI ≥ 30
BMI ≥ 30

ICU admission
IMV
In-hospital mortality
In-hospital mortality

BMI ≥ 30

In-hospital mortality
IMV

BMI:
Class I: 3034.9 kg/m²
Class II: 3539.9 kg/m²

BMI > 30
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Klang et al.

2020

USA

Mount Sinai Hospital, Mount
Sinai Brooklyn, Mount Sinai
Queens, Mount Sinai
Morningside, and Mount Sinai
West

3406

≤50: Survivors=40
Non-survivors=46.5
≥50:
Survivors=68
Non-survivors=76

57.6

In-hospital mortality
IMV

Class III:
BMI ≥ 40
kg/m²
BMI ≥ 30
with added
stratification
:
BMI of 3040

Murillo-Zamora et al.

2020

Mexico

Mexican Institute of Social
Security
Montefiore Medical Center

5393

N/A

Palaiodimos et al.

2020

USA

REVA Network
Covid-ICU
Investigators

2021

Tartof et al.

Williamson et al.

63.6

In-hospital mortality

200

64

49

In-hospital mortality

149 ICUs across 138 hospitals

4244

63

74

90-day in-hospital mortality

2020

France,
Switzer
land,
and
Belgiu
m
USA

Kaiser Permanente Southern
California

6916

49.1

45

IMV ICU admission
In-hospital mortality

2020

UK

Open SAFELY
NHS England

17,278,392

N/A

50

In-hospital mortality

BMI ≥ 40
BMI ≥ 30
BMI ≥ 35
with
following
groups:
BMI < 25
BMI of 2534
BMI ≥ 30

BMI:
Class I: 3034 kg/m²
Class II: 3539 kg/m²
Class III:
BMI > 40
kg/m²
BMI:
Class I: 3034.9 kg/m²
Class II: 3539.9 kg/m²
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Yoshida et al.

2021

USA

Tulane Medical Center and
University Medical Center

776

60.5

38.6

ICU admission
IMV
In-hospital mortality

Table 1. A qualitative summary of each study’s overall characteristics including setting, sample size, patient outcomes measured, and parameters used for
detecting obesity.

Class III:
BMI ≥ 40
kg/m²
BMI ≥ 30
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Author

BelloChavolla et
al.
Berenguer et
al.
Cariou et al.
Cravedi et al.
Cummings et
al.
Docherty et
al.
Giacomelli et
al.

Year

2020

Study design

Retrospective
observational

2020 Retrospective
Observationa
l
Retrospective
2020
cohort
Prospective
2020 observational
cohort
Prospective
2020
observational
cohort
Prospective
2020
cohort
2020

Total
number
of
participa
nts

Obesity

Mortality

OR

HR

Ninetyfive
percent
C.I.
Lower

Ninety
-five
PAdjust
percen value
ed
t C.I
(Yes/N
upper
o)

177133

29083

5332

N/
A

4035

497

181

N/
A

1.21 1.01

1.44

1317

428

140

1.28

N/A 1.10

1.47

9845

71

46

1.53

N/A 0.76

3.1

0.236
6

No

257

119

101

N/
A

0.76

0.4

1.47

N/A

Yes

20133

1685

5165

N/A

1.33 1.19

1.49

233

38

48

N/A

3.04 1.42

6.49

<0.00 Yes
1
0.004
Yes
0.0241 Yes

1.25

1.17

1.34

Hajifathalian
et al.

2020

Retrospective

770

277

88

0.56 N/A

0.34

0.93

Halvatsiotis
et al.

2020

Retrospective
observational

90

31

26

2.36 N/A

0.90

6.16

Hendren et al. 2021

Retrospective

7606

3311

1302

N/A

0.66

0.84

Klang et al.

Retrospective

3406

1231

384

0.86 N/A

0.74

1.00

0.75

<0.00 Yes
1
0.036
Yes
0.001

0.0801
0.0001

Yes

No
Yes

0.0445
2020

Yes

Model used
for
adjustment

Quality
of
Study

Cox
regression

7

Cox
regression
Logistic
regression
N/A

7
8
6

Cox
regression

8

Cox
regression

8

Cox
regression
Cox
multivariabl
e regression
N/A
Cox
regression
Multivariate
logistic
regression

8
8
6
7
8
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MurilloZamora et al.
Palaiodimos
et al.
REVA
Network
Covid-ICU
Investigators

2020

Retrospective
cohort

5393

1197

1735

2.00 N/A

1.75

2.28

2020

Retrospective

200

100

48

2.03 N/A

1.00

4.18

2021

Prospective
cohort

4244

1607

1298

0.78 N/A

71

0.90

2020

Retrospective
cohort

6916

3255

206

0.74 N/A

0.56

0.99

Williamson et
2020
al.

Retrospective
cohort

17,278,3
92

3,769,846

2954

1.17 N/A

1.12

1.22

Yoshida et al.

Case series

776

409

140

1.33 N/A

0.87

2.03

Tartof et al.

0.0001
0.05

Yes
Yes

0.004

2021

No
0.039
Yes
0.0001
<0.05

Yes
Yes

Cox
regression
Logistic
regression
Cox
regression

Multivariabl
e Poisson
regression
Cox
regression
Logistic
regression

7
8

7

7
8
7
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Table 2. Descriptive statistics of each study were provided as well as their adjustment model and quality according
to the Newcastle-Ottawa Scale.

Exposed Groups and Controls Per Study:
Table 3. List of ten studies chosen for inclusion in meta-analysis along with the relevant data regarding case counts
for groups used in factoring the odds ratios.

Study
Cravedi et al.
Hajifathalian et al.
Halvatsiotis et al.
Hendren et al.
Klang et al.
Murillo-Zamora et al.
Palaiodimos et al.
REVA Network Covid-ICU
Investigators
Tartof et al.
Williamson et al.

2020
2020
2020
2021
2020
2020
2020

71
277
31
3311
1231
1197
100

Deceased
Obese
Cases
26
22
12
490
384
458
16

2021
2020
2020

1607
3255
3769846

440
84
2954

Obese
Cases

Year

NonObese
Cases
73
493
59
4295
2175
4196
100

Deceased
Non-Obese
Cases
20
66
14
812
752
1277
32

2637
3661
13508546

858
122
6954

Meta-Analysis:
Table 4. Identification of groups according to the presence or absence of obesity as an independent variable and
COVID-19 mortality as the positive outcome.

Variable for studies

Author

1. Intervention groups
Variable for total number of cases

Obese

Variable for number of positive cases

Obese Deceased
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2. Control groups
Variable for total number of cases

Non-Obese

Variable for number of positive cases

Non-Obese Deceased

Study

Intervention

Controls

Odds ratio

Ninetyfive
percent CI

Cravedi
et al.

26/71

20/73

1.531

Hajifathal
ian et al.

22/277

66/493

Halvatsiot
is et al.

12/31

Hendren
et al.

Weight (%)
z

P

Fixed

Random

0.756 to
3.100

0.26

6.92

0.558

0.336 to
0.927

0.50

8.82

14/59

2.030

0.794 to
5.193

0.15

5.14

490/3311

812/4295

0.745

0.659 to
0.842

8.51

12.18

Klang et
al.

384/1231

752/2175

0.858

0.739 to
0.996

5.72

12.05

MurilloZamora et
al.

458/1197

1277/4196

1.417

1.239 to
1.620

7.14

12.13

Palaiodim
os et al.

16/100

32/100

0.405

0.205 to
0.799

0.28

7.14

REVA
Network
CovidICU
Investigat
ors

440/1607

858/2637

0.782

0.682 to
0.896

6.86

12.12

32

Tartof et
al.

84/3255

122/3661

0.768

0.580 to
1.019

1.61

11.06

Williams
on et al.

2954/37698
46

6954/13508
546

1.523

1.458 to
1.590

68.99

12.44

4886/37809
26

10907/1352
6235

1.273

1.228 to
1.319

100.0
0

100.00

4886/37809
26

10907/1352
6235

0.933

0.707 to
1.232

100.0
0

100.00

Total
(fixed
effects)
Total
(random
effects)

13.
12
3
0.4
86

<0
.0
01
0.
62
7

Table 5. Calculated odds ratios, weights, and 95% confidence intervals for each study along with the pooled data.
Light green shaded boxes indicate statistical significance.

Test for Heterogeneity:
Table 6. Test of heterogeneity to measure inconsistency between studies in sample. Light green shaded boxes
indicate statistical significance.

Q

252.5005

DF

9

Significance level

P < 0.0001

I2 (inconsistency)

96.44%

Ninety-five percent CI for I2

94.91 to 97.50

Publication Bias:
Table 7. Publication bias tests run to assess the validity and generalizability of sample.
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Egger's test
Intercept

-4.2547

Ninety-five percent CI

-8.8632 to 0.3539

Significance level

P = 0.0659

Begg's test
Kendall's Tau

0.2444

Significance level

P = 0.3252

Forest Plot:
Figure 3. Forest plot to visualize odds ratios for each study and the pooled odds ratios according to fixed and
random effects models.
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Discussion
Out of 22,902 of articles, 851 research publications were screened for their quality,
relevance, and applicability. According to Figure 1, seventy-five papers were eligible for
systemic review where they were screened for any relevant information regarding obesity,
COVID-19, their underlying mechanisms, and clinical management of both conditions in
patients. Fifty-eight articles were removed and deemed unfit for further mention due to
incomplete case counts for obesity and COVID-19 mortality. Meta-analyses were excluded due
to lack of clinical data regarding obesity and COVID-19 mortality retrieved directly from
medical centers. Literature reviews, while useful for understanding the physiological relationship
between obesity and COVID-19, were not counted due to lack of any quantitative data besides
comparing statistical measurements for obesity and COVID-19 outcomes separately. In the end,
seventeen studies were found to contain relevant information on patient outcomes with 10/17
being used to construct the meta-analysis due to their cross-sectional statistics.
As studies have begun to show an association between obesity and COVID-19, many
researchers have chosen to use BMI as their operational definition for excess body fat as a
measure of clinical obesity. Unfortunately, this heavy reliance on BMI tends to leave out millions
of vulnerable patients with BMIs below the cutoffs for overweight and obesity at 25 and 30,
respectively. While these individuals may not qualify as obese, they tend to display the same
mortality risk for COVID-19. To account for this discrepancy, VAT or visceral adipose tissue
has become a new operational tool for categorizing obese patients along with other measures of
truncal obesity including waist circumference, waist-to-hip ratio, waist index, and waist-to-height
ratio.
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Regardless, dozens of meta-analyses and systematic studies globally back up the
consistent pattern of obesity-induced COVID-19 severity and death. In Brazil, obesity
prevalence correlated with overall COVID-19 mortality rates across 26 state capitals with a
statistically significant correlation coefficient of 0.38 [8]. A medium positive correlation (r =
0.46; p < 0.001) was also found between total volume of COVID-19 infections and obesity using
pooled data from 54 countries [34]. In a statistical review of 61 studies, obesity was associated
with a 3-fold increased risk of severe disease and 1.36-fold greater chance of mortality [29].
Twenty cohort studies of 28,355 hospitalized COVID-19 patients also displayed a pooled
adjusted OR of 2.02 in favor of obese patients obtaining a negative outcome [30]. In a study
done on 6916 COVID-19 patients from Kaiser Permanente South California HMO, BMI
followed a J-shaped distribution with increased risk ratios of 1.81 for underweight (<18.5 kg/m²)
and 4.18 for the highest category of obesity (≥45 kg/m²) [66]. 45,650 participants in 30 studies of
BMI-defined obesity were found to have increased risk for ICU admission, hospitalization,
intensive mechanical ventilation, and mortality with overall ORs of 1.67 (univariate) and 2.09
(multivariate) for severe COVID-19 [32]. Overall, obese patients infected with COVID-19 could
be four times more at-risk for death relative to the overall population with young-adult males
being the most vulnerable group [66].
Similarly, a total of 50 numerous studies and over 18 million subjects mostly located in
the U.S.A. further back up the BMI-mortality axis. Odds ratios of 1.65. 1.91, and 1.71 for BMI
ranges: BMI ≥ 30, 35-39.9, and BMI ≥40 respectively show a near doubling of the mortality risk
with obese patients making up a greater proportion of the non-survivors as a result [71]. In
another meta-analysis done using 41 studies, 11 measuring hospitalization, 15 measuring ICU
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admission, and 14 measuring invasive mechanical ventilation were compiled together in a pooled
analysis which found a 1.5x increased incidence for each of the three outcomes in COVID-19
patients with obesity compared to those without [72]. A meta-analysis of 10 studies with 10,233
participants revealed similar findings with obese COVID‐19 patients having higher odds of poor
outcomes compared with better outcomes with a pooled OR of 1.88 (95% CI: 1.25–2.80; p =
0.002) [42]. It can be concluded that obesity affects COVID-19 patient outcomes, but the manner
in which it happens remains to be understood.
Obesity is a chronic disorder meaning it has long-term consequences that require
significant lifestyle changes to reverse or prevent. Obesity weakens the body’s immune system
making it susceptible to chronic hyperinflammatory distress leading to prolonged duration of
illness and increased viral shedding [9]. Difficulties in pulmonary ventilation and gas exchange
are also exacerbated along with thromboembolism or blood clotting which together led to
increased mortality [9]. Physical activity is a solution to this by reducing oxidative stress through
inhibition of both inflammation and macrophage activation [9]. While it is best to prevent obesity
through a proper diet and lifestyle, individuals who are already obese can still engage in healthy
practices to lower their baseline weight.
While the purpose of this study is to focus on in-hospital deaths of obese COVID-19
patients, there are many studies that choose to focus on alternative outcomes that can shed
equivalent light on the consequences of having both disorders. At New York Presbyterian and
Columbia University-Irving Medical Center, Dr. Argenziano and others found obesity to be a
common baseline comorbidity in almost half of all patients with reported BMI while obese
patients alone made up around 45% of ICU admissions [2]. Instead of in-hospital mortality,
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COVID-19 severity was used as the final outcome in a groundbreaking study at the Third
People’s Hospital in Shenzhen, China that found obese patients to be 3.40 times more likely to
develop severe disease after adjusting for age, sex, comorbidities, and other epidemiological
qualities [6]. Highlighting other less negative patient outcomes can still illustrate the nature of
COVID-19 in vulnerable populations.
Five studies listed in Table 1 and 2 used hazard ratios to measure the relationship
between obesity and death from COVID-19. Due to their small sample size, they were not
selected for separate meta-analysis but were left in for comparison as their inclusion indicates a
relationship between obesity and COVID-19 mortality. According to Figure 2 and Table 6, of the
ten studies used, the pooled OR was 0.933 using the random effects model which was used due
to 94-95% heterogeneity of the studies. In Table 5 and 6, this indicates a non-significant
relationship ( p > 0.001) between obesity and mortality alone for COVID-19. However, not
including the five other studies and what the fixed-effect model states to be a significant risk of
mortality from COVID-19 in obese patients suggests that obesity may impact COVID-19 in
other ways. For example, multiple studies that have shown obesity to raise the chances of
COVID-19 mortality used higher BMI cutoffs as well as severity as a parameter instead of only
mortality. Such adjustments may skew the data and exaggerate the effect of obesity on COVID19 outcomes. In addition, the patient ample itself tends to not always be randomized but selfselected for patients with certain pre-existing conditions. The effect of obesity on COVID-19 that
is frequently detected may still be the result of other undetected confounding factors such as
diabetes, hypertension, and other comorbidities frequently present in a major share of COVID-19
patient samples.
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Any discrepancies between this meta-analysis and others may be because of differences
in grouping. According to Tables 3 and 4, the four groups chosen were obese deceased, nonobese deceased, obese alive, and non-obese alive. Using binary outcomes, one can use case
counts to calculate effect sizes to measure the relative risk of mortality in obese COVID-19
patients compared to controls. In similar statistical reviews, there was not a similar crosssectioning of patient populations due to lack of significant mortality data or a desire to measure
other more common outcomes instead. Furthermore, certain studies have self-selected patient
samples that may not accurately reflect the general patient population. For example, Cravedi’s
study focuses on kidney transplantation participants while the Palaiodimos study only counts the
first 200 patients admitted which could be considered a form of sampling bias. Overall, the study
designs, patient population characteristics, and data collection methods of the ten studies chosen
may have had an impact on the final outcomes detected.
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Conclusion:
The systemic review and meta-analysis have elucidated the variables symptomatic of
obesity that also functioned as negative effectors worsening the severity of COVID-19 leading to
poor patient outcomes. This included mediating variables such as pulmonary distress which
amplify symptoms of obesity in their effects on COVID-19 severity. Furthermore, discussion of
inflammatory pathways that decrease immune responsiveness was necessary to further elaborate
on the possible mechanisms underlying any correlations between obesity and COVID-19
mortality. After all risk factors were assembled, they were compared to identify how strongly
they mediated COVID-19 mortality and patient outcomes such as hospitalization. Studies were
grouped according to patient outcomes with odds ratios being used to indicate the relative
likelihood of obese patients obtaining those clinical results compared to controls.
Future studies must disaggregate data regarding mortality and comorbidities while
adopting more novel parameters for measuring obesity. As it stands, an over reliance on BMI
masks the true role that visceral adipose tissue and truncal obesity plays in longitudinal health
outcomes. Researchers can continue to study obesity-induced mortality through other underused
parameters like VAT or waist index. In addition, more attention could be given to type II
diabetes mellitus as it occurs often in obese COVID-19 patients. In Mexico, COVID-19 patients
with type II diabetes mellitus were found to have particularly higher rates of mortality (21.8% vs
7.7%), hospitalization, ICU admission, requirement for invasive ventilation, and confirmed
pneumonia compared with those without diabetes [3]. Increased vulnerability to COVID-19 in
patients with diabetes may be explained by several mechanisms, including an increased lung
angiotensin-converting enzyme (ACE2) expression and elevated circulating levels of furin, a
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protease that facilitates viral entry to adipose cells, and a decreased removal of SARS-CoV-2
viral particles in subjects with diabetes and/or hypertension associated with ACE2 expression
[3]. As new strains like Omicron are tracked, long-term symptom detection in obese COVID-19
patients must be prioritized for future research endeavors.
The overall scope of this project is to study the effect on mortality caused by the negative
combination effects of obesity and SARS-CoV-2 in affected patients using epidemiological
methods on health data in the form of BMI and VAT measures. Over the course of the COVID19 pandemic, multiple studies have shown that obesity is an important comorbidity that can
increase hospitalization rates and force patients to heavily rely on IMV and ICU treatment for
any sort of recovery. On top of that, any sort of recovery is unlikely for certain obese patients
given the increased odds of mortality resulting from the mediating effects of obesity on any
immune response to COVID-19. Thus, the unique goals of this study were to build on previous
reports by narrowing the focus on measuring obesity through visceral adipose tissue instead of
BMI and analyze multiple clinical outcomes instead of just mortality odds. Such a study as this
would allow for better understanding of possible biochemical pathways underlying the
exacerbation of symptoms in COVID-19 patients for future studies. The results of this study may
pave the way for novel approaches to treating obesity and COVID-19 complications through
weight loss interventions and antiviral drugs. Furthermore, with millions of obese people
worldwide--and some who go undiagnosed---there is an urgent need to understand how obesity
and COVDI19 upregulate each other. Overall, a proper systemic review with greater clinical data
spanning the entire length of the pandemic instead of just the first few months should allow
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physician scientists a more complete understanding of how two of humanity’s greatest health
crises are teaming up to increase the global disease burden.
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